Okay, let's tackle this question about the mechanism of radioiodine in treating papillary thyroid carcinoma. First, I need to recall how radioiodine works. I know that thyroid cells take up iodine, and papillary carcinomas are usually differentiated, so they might retain this ability.

The question is asking how radioiodine destroys the neoplastic cells. The options aren't provided, but I can think of possible mechanisms. Radioactive iodine (I-131) is used because thyroid cells have sodium-iodide symporters that transport iodine into the cell. Once inside, the radiation damages the DNA, leading to cell death. So the key here is the uptake via the sodium-iodide symporter.

Now, the distractors might include other mechanisms like direct DNA damage without uptake, or other pathways like apoptosis or necrosis. But the correct answer should focus on the symporter-mediated uptake. Let me make sure. The sodium-iodide symporter (NIS) is crucial for iodine uptake in thyroid cells. In papillary carcinoma, since these are differentiated, they express NIS, allowing radioiodine to target them specifically. So the destruction is due to the radiation emitted after the iodine is taken up via NIS.

The other options might be things like receptor-mediated endocytosis or other transporters, but those aren't the main ones here. Also, maybe options about non-specific toxicity, but radioiodine is specific because only cells with NIS take it up. So the correct answer is about the sodium-iodide symporter. The clinical pearl here is that follicular and papillary carcinomas are more likely to take up radioiodine compared to anaplastic, which doesn't. That's a key point for exams.

**Core Concept**
Radioiodine (I-131) selectively targets thyroid tissue, including papillary carcinomas, by exploiting the **sodium-iodide symporter (NIS)**. This transporter facilitates iodine uptake into thyroid follicular cells, enabling radiation-induced DNA damage and apoptosis in neoplastic cells.

**Why the Correct Answer is Right**
The **sodium-iodide symporter (NIS)** is expressed in differentiated thyroid cells, including papillary carcinoma cells. Radioiodine is actively transported into these cells via NIS, where emitted beta radiation causes localized DNA damage, leading to tumor cell destruction. This mechanism is specific to thyroid-derived cells that retain NIS expression.

**Why Each Wrong Option is Incorrect**
**Option A:** *Receptor-mediated endocytosis* is incorrect; radioiodine uptake does not involve cell surface receptors.
**Option B:** *Direct DNA binding* is incorrect; iodine requires intracellular accumulation (via NIS) to exert cytotoxic effects.
**Option C:** *Mitochondrial disruption* is not the primary mechanism; radiation-induced DNA damage is central.

**Clinical Pearl / High-Yield Fact**
Papillary and follicular carcinomas (differentiated thyroid cancers) retain NIS expression, making them responsive to radioiodine. Anaplastic thyroid cancer lacks NIS and is **not** treatable with I-131—this distinction is critical for exam questions on thyroid cancer management.

**Correct Answer: C. Sodium-iodide symporter-mediated uptake**

✓ Correct Answer: B. Beta rays